Related Experiment Video

Updated: Feb 25, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K

Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5

Xiaocui Fang1, Hanyi Xie2, Hongyang Duan1

  • 1CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, P. R. China.

Plos One
|August 10, 2017
PubMed

Insights

A novel peptide (E5) delivered via PEG-PE micelles (M-E5) effectively targets cancer cells by inhibiting the CXCR4/CXCL12 axis. This micelle system enhances drug delivery and shows potential for improving solid tumor therapies.

Area of Science:

  • Oncology
  • Nanomedicine
  • Molecular Biology

Background:

  • Cancer metastasis is a primary cause of mortality worldwide.
  • The CXCR4/CXCL12 axis is implicated in tumor growth, angiogenesis, and metastasis.
  • Targeting this axis presents a significant therapeutic opportunity.

Purpose of the Study:

  • To develop and evaluate a novel peptide-based CXCR4 antagonist (E5) encapsulated in PEG-PE micelles (M-E5) for cancer therapy.
  • To assess the targeting efficiency and anti-metastatic effects of M-E5.
  • To investigate the potential of PEG-PE micelles as a co-delivery system for E5 and chemotherapy drugs.

Main Methods:

  • Synthesis of a novel peptide (E5) targeting the CXCR4/CXCL12 axis.
  • Encapsulation of E5 into PEG-PE micelles to form M-E5.
  • Evaluation of M-E5's affinity and tumor cell migration inhibition in CXCR4-overexpressing cell lines (MCF-7, HepG2).
  • Co-delivery studies with doxorubicin (Dox) to form M-E5-Dox and assessment of its impact on signaling pathways (Akt, Erk, p38/MAPK).

Main Results:

  • M-E5 demonstrated enhanced affinity for CXCR4-overexpressing tumor cells compared to free E5.
  • M-E5 significantly inhibited tumor cell migration.
  • PEG-PE micelles effectively encapsulated E5, improving its targeting efficiency.
  • M-E5 potentiated doxorubicin's efficacy by down-regulating key pro-survival signaling pathways.

Conclusions:

  • PEG-PE micelles serve as a promising delivery vehicle for the peptide E5.
  • M-E5 exhibits potential as a therapeutic agent for solid tumors.
  • The M-E5-Dox system offers a dual-action approach, enhancing chemotherapy effectiveness.

More Related Videos

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles09:57

Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles

Published on: June 28, 2021

2.4K
A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 406:56

A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4

Published on: March 10, 2018

14.6K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
683